13
Participants
Start Date
February 28, 2006
Primary Completion Date
January 31, 2010
Study Completion Date
January 31, 2010
Intravenous Daclizumab
Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
Intravenous Infliximab
Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
Observation
Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
Oral Rapamycin
Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Eye Institute (NEI)
NIH